In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.88.
According to TipRanks, Gershell is a 3-star analyst with an average return of 1.6% and a 35.14% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Cue Biopharma, and Crinetics Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $4.75 average price target, a 152.66% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $3.00 price target.
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $48.32 million and a GAAP net loss of $12.19 million. In comparison, last year the company earned a revenue of $29.73 million and had a GAAP net loss of $21.83 million
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year. Most recently, in March 2024, John Johnson, a Director at XERS bought 215,600.00 shares for a total of $429,044.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals (XERS) Company Description:
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
- Xeris Biopharma reports Q1 EPS (14c), consensus (12c)
- Xeris Biopharma enters collaboration, license agreement with Beta Bionics
- Xeris Biopharma enters exclusive license agreement with Beta Bionics
- Xeris Biopharma initiated with an Outperform at Oppenheimer
- Acelyrin price target raised to $13 from $11 at Wells Fargo
